New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
Featured oral presentation on the effect of sotagliflozin on cardiovascular mortality and hospital readmission rates for heart failure at 30-...
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD